Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients With Early Alzheimer’s Disease

“Over the past several months, we have listened to the feedback of our stakeholders, and we are now taking important actions to improve patient access to ADUHELM,” said Michel Vounatsos, Chief Executive Officer at Biogen. “Too many patients are not being offered the choice of ADUHELM due to financial considerations and are thus progressing beyond the point of benefitting from the first treatment to address an underlying pathology of Alzheimer’s disease. We recognize that this challenge must be addressed in a way that is perceived to be sustainable for the U.S. healthcare system.” Read More